Avanafil

Chenglian Pharmaceutical is an innovative high-tech pharmaceutica'l enterprise that is market-oriented and realizes industrial development th‍rough R&D innovation and technology transformation.

key word:

Pharmaceutical technology

Category:

Related

Product Description

Integrity, innovation, cooperation, sharing, win-win

The company integrates multiple resources and strives to build a large★ health industry finance platform company integrating pharmaceutical, intellige✘nt medical, bio pharmaceutical R&D, industrial production an>d sales.

The chemical reactions involved in the existing products i₹nclude Foucault reaction, nitration reaction, sulfonation reacti€on, hydrogenation reaction, fluorination reaction, chlorination reaction, bromination reactio™n, diazotization reaction, format reaction, etc.

Related products

Sitagliptin Phosphate Monohydrate

Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4) inhibitor developed by Merck. In October> 2006, Sitagliptin phosphate Januvia was approved by FDA as the first DPP4 inhibitor for the λtreatment of type ⅱ diabetes mellitus. The characteri stics of this drug are that it can stimulate insulin secretion w hile reducing hunger without causing weight gain. Hypoglycφemia and edema will not occur, and it is suitable for diabetλic patients with poor blood glucose control and frequent hypoglyceσmia.

Sumatriptan Succinate

Medication for migraine

Vildagliptin

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market-or<iented and realizes industrial development through R&D innovation  and technology transformation.

Ketoprofen

The non-steroidal anti-inflammatory drug ketoprofen is one of the most important products for t§he treatment of arthritis. It is well tolerated and has a low incidence of side effe cts

Pranlukast

Pranlukast, developed by Ono, is one of the three major leukotriene receptor antagonists. In cl¶inical application, it has good therapeutic effect on atopic asthma and other types of bro§nchial asthma, and the market prospect is huge. In the major category of asthma drugs, ©leukotriene receptor antagonists have the fastest growing market share.

Avanafil

Chenglian Pharmaceutical is an innovative high-tech phar maceutical enterprise that is market-oriented and realizes industrial developmen£t through R&D innovation and technology transformation.

Donepezil HCL

Treatment of mild to moderate Alzheimer's syndrome. It is the second drug approved by FDA f¶or Alzheimer's disease in the United States. Its treatment reaches the target dose and has l∞ow toxic and side effects. It has been widely recogn•ized by our medical community, and good tolerance is its biggest adv•antage. In October 1999, Donepezil was launched in China und er the trade name "Aricept", which is the main chemical drug against Alβzheimer's disease. At present, CFDA has approved a number of domestic enterprises to produce donep¶ezil preparations, the main dosage forms are tablets, capsules, dispersive tablets, oral disin☆tegrating tablets.

Almotriptan

Migraine medication for adolescents

Apixaban

English name Apixaban Trade name ELIQUIS, tablet: Apixaban (Eliquis, Bristol-Myers Squibb/Pfizer>), a direct oral factor Xa inhibitor, was approved for use in the 27 EU member states. The world's• first drug approved to prevent venous thromboembolis¶m (VTE) in adult patients undergoing elective hip or knee replacement . From June 2019 to June 2020, the annual sales of apixaban products overseas reached abouαt $15.4 billion, with a year-on-year growth of nearly 32%, and the API♠ consumption reached about 23,960 kg, with a year-on-year growth of about 2↑8%. Compared with its main competitor, Rivaroxaban, the drug's annual overseas sales are aboutγ $4.5 billion higher.

Lenvatinib

Chenglian Pharmaceutical is an innovative high-tech pharmaλceutical enterprise that is market-oriented and realizes industrial development through R&D innβovation and technology transformation.

Clofarabine

It is a nucleotide analogue developed by Bioenvision and manufactured by Genzyme. On <December 29, 2004, it was approved by FDA for the treat→ment of refractory or relapsed acute lymphoblastic leukemia (ALL) in  children.

Upadacitinib(Scientific research)

Chenglian Pharmaceutical is an innovative high-tech phσarmaceutical enterprise that is market-oriented and realizes industrial devπelopment through R&D innovation and technology transformati↔on.

Product Consulting

Our staff will contact you within 24 hours (working days). If you need other services, E™-mail: 2880705932@qq.com
Submit